Lucio Tentori
Department of Neuroscience
University of Rome Tor Vergata
Via Montpellier 1
00133 Rome
Italy
Name/email consistency: high
- Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? Tentori, L., Graziani, G. Pharmacol. Res. (2007)
- Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Tentori, L., Leonetti, C., Scarsella, M., Vergati, M., Xu, W., Calvin, D., Morgan, L., Tang, Z., Woznizk, K., Alemu, C., Hoover, R., Lapidus, R., Zhang, J., Graziani, G. Int. J. Oncol. (2005)
- Chemopotentiation by PARP inhibitors in cancer therapy. Tentori, L., Graziani, G. Pharmacol. Res. (2005)
- Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Tentori, L., Leonetti, C., Scarsella, M., D'Amati, G., Vergati, M., Portarena, I., Xu, W., Kalish, V., Zupi, G., Zhang, J., Graziani, G. Clin. Cancer Res. (2003)
- Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Tentori, L., Leonetti, C., Scarsella, M., d'Amati, G., Portarena, I., Zupi, G., Bonmassar, E., Graziani, G. Blood (2002)